甲磺酸阿帕替尼治疗50例晚期原发性肝癌的效果分析  

Effect of apatinib mesylate in the treatment of 50 cases of advanced primary hepatocellular carcinoma

作　　者：韦亚娜[1] 牙韩达 Wei Yana;Ya Handa(Department of Oncology, Hechi People' s Hospital, Hechi, Guangxi, 547000, China)

机构地区：[1]河池市人民医院肿瘤内科

出　　处：《当代医学》2019年第29期107-109,共3页Contemporary Medicine

摘　　要：目的探讨阿帕替尼治疗晚期原发性肝癌患者的临床效果。方法用“随机法”将本院50例晚期原发性肝癌患者均分为对照组和观察组,其中对照组予以安慰剂和其他治疗,观察组给予阿帕替尼治疗,对比两组患者的临床缓解率、生存期和不良反应发生情况。结果观察组患者临床缓解率比对照组高,生存期长于对照组(P<0.05),两组患者不良反应总发生率比较,差异无统计学意义。结论对晚期原发性肝癌患者实施阿帕替尼治疗可以有效提高临床缓解率,延长患者的生存期,安全性较高,值得大力推广。Objective To investigate the clinical effect of apatinib in the treatment of advanced primary liver cancer. Methods 50 patients with advanced primary liver cancer in our hospital were divided into control group and observation group by "random method". The control group was given placebo and other treatment, while the observation group was given Apatinib treatment. The clinical remission rate, survival time and adverse reactions of the two groups were compared. Results The clinical remission rate of the observation group was higher than that of the control group, and the survival time was longer than that of the control group (P<0.05). There was no significant difference in the total incidence of adverse reactions between the two groups. Conclusion Appatinib can effectively improve the clinical remission rate and prolong the survival time of patients with advanced primary hepatocellular carcinoma. It is safe and worthy of vigorous promotion.

关 键 词：阿帕替尼 晚期原发性肝癌 临床缓解率 生存期 不良反应 

分 类 号：R735.7[医药卫生—肿瘤]